Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
about
Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials.Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committeeEvaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticlesLong-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020ALong-term treatment of patients with HIV-1: the role of atazanavirEffect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.A simple, efficient, and sensitive method for simultaneous detection of anti-HIV drugs atazanavir, ritonavir, and tenofovir by use of liquid chromatography-tandem mass spectrometry.Atazanavir: simplicity and convenience in different scenarios.Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsulesLopinavir/ritonavir in the treatment of HIV-1 infection: a review.Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.Role of atazanavir in the treatment of HIV infectionAtazanavir: its role in HIV treatmentImproving outcomes in state AIDS drug assistance programs.Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy.HIV protease inhibitors: recent clinical trials and recommendations on use.Differences in implementation of HIV/AIDS clinical research in developed versus developing world: an evidence-based review on protease inhibitor use among women and minorities.A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.Switch strategies in antiretroviral therapy regimens.[HIV infection : chronic disease with comorbidities].Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected PatientsCardiovascular disease associated with the human immunodeficiency virus: an update.A single centre cohort experience with a new once daily antiretroviral drug.Revealing the metabolic sites of atazanavir in human by parallel administrations of D-atazanavir analogs.Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients.Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.Identification and structural elucidation of in vitro metabolites of atazanavir by HPLC and tandem mass spectrometry.Diarrhea associated with lopinavir/ritonavir-based therapy: results of a meta-analysis of 1469 HIV-1-infected participants.Baseline lipid levels rather than the presence of reported body shape changes determine the degree of improvement in lipid levels after switching to atazanavir.Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations
P2860
Q35079510-F70AD2E3-0A9D-49BA-99B3-655692A628CAQ35109199-BCE72DC4-BEA8-4C4E-9658-C3B42F4681C8Q35124959-C4B9B5D1-CE1A-4C32-BF52-9D1624821539Q35147145-8E19DD4C-1B23-4C67-B7BF-73AC79A25BD0Q35163596-063EC231-DBF7-4DD7-8E1B-DD7E2CF7F897Q35557219-367D4F58-4629-4AE1-BF27-158DEFFA6E71Q36094771-70E1557D-7CB4-48B0-8583-DA66742155FAQ36158376-35B77898-65A5-4EA5-8D18-5DF57F4B3E86Q36765802-52EB7723-815E-4A59-A46D-DE4857C2B802Q36926668-682F5682-0C96-4C49-A60B-025AB2A7C81CQ37052827-AA517B63-A36F-48DA-A06C-47206F1F8CA5Q37111827-8F302374-3443-450D-9298-01124DF167C4Q37230298-DCA41EE8-DE85-4197-9CAB-52CCEABBB1A3Q37249418-C2AEB879-1AB3-4E27-A640-1DB9F99B00C8Q37415433-A7E167C0-B896-4AF8-B481-BD21836EC3F5Q37439827-7E42CDA1-CD7D-4CF7-8793-49C49ADE516CQ37519715-4B90998A-39FB-4683-9864-20CEDFAA350CQ38069146-852D276E-B89F-4538-9068-DD36CC17E447Q38169257-E9A14377-0F42-4849-B007-FEA02FF53DBBQ38235295-5B02FFC3-7590-406A-95D1-1E3F789450C2Q38413754-407DF004-4582-4321-8157-7AA28EBAC3A7Q39007008-17F47D59-520A-49FD-9967-7B4BFE77886CQ40555236-2CDCCC8E-1FF9-491D-A2CD-DB471A8C0AD5Q41494718-5E18688A-3BE5-4BBF-AEAB-83AB15B3B7DFQ41751842-AB7F723C-A860-4475-8547-03F2E12A0C3DQ42107646-26175943-4C5F-4BCF-AFC9-E9085A4FBB6BQ42265837-4D8FEDC7-9E9D-4B67-B7C5-ABFC8F6B0951Q42936157-53FC00A1-2F55-4BF8-9B04-353D613AA4A5Q43774080-520DEA40-8CBA-46A2-A299-A165235EA8F2Q44401027-21BD51DD-46DE-45D2-80E8-8252D6206F28Q44641855-CBBD1D38-BEDE-4619-87A3-B199603B32B1Q45919620-5490AB9C-4412-4A75-A4B7-891B80E2B91FQ45919628-1FD75731-7492-4FAA-9E37-4B2ADF2C55A6Q58780819-ED1B0C94-E23A-4601-8C33-10D28EC6762F
P2860
Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Comparison of atazanavir with ...... andomized multinational trial.
@en
Comparison of atazanavir with ...... andomized multinational trial.
@nl
type
label
Comparison of atazanavir with ...... andomized multinational trial.
@en
Comparison of atazanavir with ...... andomized multinational trial.
@nl
prefLabel
Comparison of atazanavir with ...... andomized multinational trial.
@en
Comparison of atazanavir with ...... andomized multinational trial.
@nl
P2093
P356
P1476
Comparison of atazanavir with ...... andomized multinational trial.
@en
P2093
BMS AI424-043 Study Group
J Gonzalez-Garcia
L Nieto-Cisneros
R McGovern
W J Fessel
P304
P356
10.1185/030079905X65439
P407
P577
2005-10-01T00:00:00Z